Vanguard Global Advisers’s Solid Biosciences SLDB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$375K Sell
51,864
-6,727
-11% -$60.9K ﹤0.01% 2221
2026
Q2
$585K Buy
58,591
+22,189
+61% +$168K ﹤0.01% 2029
2026
Q1
$262K Buy
+36,402
New +$234K ﹤0.01% 2310

Other funds holding SLDB

Vanguard Global Advisers's SLDB Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Solid Biosciences (SLDB) stake by 11% in Q3 2026, selling an estimated $60.9K and leaving 51,864 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Vanguard Global Advisers first reported a position in SLDB in Q1 2026 and has held it in 3 quarters since. The position peaked at $585K in Q2 2026. 158 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

  • Vanguard Global Advisers held 51,864 shares of Solid Biosciences worth $375K as of Q3 2026.
  • Vanguard Global Advisers sold 6,727 Solid Biosciences shares in Q3 2026, an estimated $60.9K.
  • Solid Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2221 holding.
  • Vanguard Global Advisers first reported a position in Solid Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Solid Biosciences position peaked at $585K in Q2 2026.
  • 158 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.